Connect with us

Health

Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization – PRNewswire

/PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO®…

Published

on

Article feature image

RARITAN, N.J., May 16, 2021 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent…

Click here to view the original article.

Continue Reading
Advertisement

You might also like ...

Article feature image
Study claims skipping morning meal can have ill-effects on health – Devdiscourse
Third wave of Covid ‘definitely under way’ in UK, says expert – The Guardian